Format

Send to

Choose Destination
Arch Intern Med. 2001 Oct 22;161(19):2293-300.

Continuous subcutaneous insulin infusion: a comprehensive review of insulin pump therapy.

Author information

1
Diabetes and Metabolic Diseases Center, Section of Endocrinology, Christiana Care Health Services, 700 Lea Blvd, Suite 300, Wilmington, DE 19802, USA. JLenhard@ChristianaCare.org

Abstract

A tremendous amount of data suggest that near-normal glycemic control prevents or delays complications of diabetes, which has led to a dramatic increase in continuous subcutaneous insulin infusion (CSII) or insulin pump use. In this article, the data supporting CSII in type 1 diabetes is reviewed, and the advantages and disadvantages of CSII are analyzed. In addition, CSII use in specific situations is examined, including during childhood and pregnancy and while exercising. The published articles suggest that CSII provides better glycemic control than does conventional therapy and comparable to or slightly better control than multiple daily injections. The use of CSII may be especially indicated during pregnancy or for preconception care and for diabetes presenting in childhood or adolescence.

PMID:
11606144
DOI:
10.1001/archinte.161.19.2293
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Silverchair Information Systems
Loading ...
Support Center